OVERVIEW

Corporate Profile

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Recent News

More>>
  • Jul 07, 2020

    Funding supports late-stage clinical development, including pivotal Phase 3 clinical trial to support licensure OWS award funds large-scale manufacturing of NVX-CoV2373, including production of 100 million doses starting in late 2020 GAITHERSBURG, Md....More>>

  • Jul 02, 2020

    Frank Czworka appointed SVP, Global Sales Brian Webb promoted to SVP, Manufacturing GAITHERSBURG, Md. , July 02, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the...More>>

  • Jun 29, 2020

    GAITHERSBURG, Md. , June 29, 2020 (GLOBE NEWSWIRE) -- Novavax , Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Ben Machielse as Executive Vice President, CMC, with responsibility for...More>>

Stock Quote

This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings.

Accept